KB1541 Pharmaceutical Composition for Mitochondrial Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments fail to effectively address the malfunction of mitochondria, which induces cell aging and related diseases by increasing ROS, reducing ATP production, and impairing energy efficiency.
Innovation Solution
A pharmaceutical composition comprising KB1541, which activates 14-3-3 zeta/delta protein, increases cristae, and activates ATP synthase, thereby enhancing autophagy and reducing ROS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mitochondria malfunction occurs, then ROS increases and ATP production decreases, but existing treatments fail to effectively address this malfunction
Solution Approach 1:
The patent uses 14-3-3 zeta/delta protein as an intermediary mediator that binds to ATP synthase and facilitates its proper function. This intermediary protein helps transfer the beneficial effects of KB1541 treatment to the mitochondrial machinery, resolving the contradiction by introducing a mediating element that restores ATP production while reducing ROS without requiring direct intervention in the malfunctioning mitochondria themselves
Solution Approach 2:
The patent changes the chemical parameter of KB1541 compound to specifically target and upregulate 14-3-3 zeta/delta protein expression. By modifying the chemical composition and dosage parameters of KB1541, the treatment achieves optimal upregulation of the intermediary protein, which in turn restores mitochondrial function, reduces ROS, and increases ATP production simultaneously
2Use of energy by moving object
If ATP synthase is not activated, then energy production is insufficient, but activating ATP synthase requires specific protein interactions that are not well understood
Solution Approach 1:
The patent introduces 14-3-3 zeta/delta protein as an intermediary that simplifies the complex protein interaction required for ATP synthase activation. This intermediary protein serves as a bridge between KB1541 treatment and ATP synthase, making the activation process more tractable and understandable by breaking down the complex direct interaction into manageable steps involving the intermediary mediator
Solution Approach 2:
The patent replaces the need for complex mechanical understanding of protein-protein interactions with a chemical solution. By using KB1541 compound to chemically upregulate 14-3-3 zeta/delta protein expression, the treatment bypasses the need to mechanically manipulate or directly understand the intricate physical interactions between proteins, substituting chemical regulation for mechanical complexity
3Shape
If cristae structure is reduced, then mitochondrial function deteriorates, but increasing cristae requires specific protein upregulation
Solution Approach 1:
The patent changes the chemical parameter of KB1541 dosage and administration to achieve optimal upregulation of 14-3-3 zeta/delta protein. By carefully adjusting the chemical parameters of KB1541 treatment, the patent achieves effective protein upregulation that leads to cristae restoration without requiring complex manufacturing processes or difficult-to-implement protein delivery systems
Solution Approach 2:
The patent replaces complex mechanical or biological processes for increasing cristae with a chemical approach. By using KB1541 compound to chemically induce 14-3-3 zeta/delta protein upregulation, the treatment simplifies the process of restoring cristae structure, making it more accessible and easier to implement compared to direct protein delivery or genetic manipulation approaches
Data Source
AI summary
HTS screening was performed regarding cell proliferation, one of symptoms of senescence. As a result, KB1541, which was the most effective on cell proliferation, was earned. The present invention described how the compound regulates cell proliferation and senescence. The present invention uncovered what proteins interacted with the compound using streptavidin-magnetic beads after treating with biotin-connected KB1541. Consequently, it was identified that mitochondrial proteins interacted with the compound. In ATP assay, electron microscope and IP assay, the inventors identified that the compound regulated mitochondrial proteins and thereby increased ATP production as well as recovered senescence.